company background image
MMED logo

Mind Medicine (MindMed) NEOE:MMED Stock Report

Last Price

CA$14.90

Market Cap

CA$693.6m

7D

0%

1Y

200.4%

Updated

07 Jul, 2024

Data

Company Financials +

Mind Medicine (MindMed) Inc.

NEOE:MMED Stock Report

Market Cap: CA$693.6m

MMED Stock Overview

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details

MMED fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Mind Medicine (MindMed) Inc. Competitors

Verano Holdings

NEOE:VRNO

CA$678.0m

Cresco Labs

CNSX:CL

CA$574.1m

Knight Therapeutics

TSX:GUD

CA$523.2m

Cronos Group

TSX:CRON

CA$1.1b

Price History & Performance

Summary of share price highs, lows and changes for Mind Medicine (MindMed)
Historical stock prices
Current Share PriceUS$14.90
52 Week HighUS$16.40
52 Week LowUS$3.30
Beta2.39
1 Month Change0%
3 Month Change0.81%
1 Year Change200.40%
3 Year Changen/a
5 Year Changen/a
Change since IPO145.27%

Recent News & Updates

Recent updates

Shareholder Returns

MMEDCA PharmaceuticalsCA Market
7D0%2.4%-2.0%
1Y200.4%-26.7%15.2%

Return vs Industry: MMED exceeded the Canadian Pharmaceuticals industry which returned 16% over the past year.

Return vs Market: MMED exceeded the Canadian Market which returned 10.7% over the past year.

Price Volatility

Is MMED's price volatile compared to industry and market?
MMED volatility
MMED Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market2.9%

Stable Share Price: MMED has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MMED's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a57Rob Barrowwww.mindmed.co

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc. Fundamentals Summary

How do Mind Medicine (MindMed)'s earnings and revenue compare to its market cap?
MMED fundamental statistics
Market capCA$693.64m
Earnings (TTM)-CA$170.82m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Is MMED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MMED income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$125.32m
Earnings-US$125.32m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.74
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio7.2%

How did MMED perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/07 08:02
End of Day Share Price 2024/04/10 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mind Medicine (MindMed) Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Sumant Satchidanand KulkarniCanaccord Genuity
Tania Armstrong-WhitworthCanaccord Genuity